BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Gan & Lee Launches Third Phase 3 Trial of Once-Monthly GLP-1 Bofanglutide for Long-Term Weight Maintenance

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of...

November 28, 2025 | News

HKeyBio Expands Its Autoimmune and Allergy R&D Capabilities With HKEY-AIDMD 3.0 Platform Upgrade

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBi...

November 28, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech

Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...

November 27, 2025 | Analysis

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Harbour BioMed Deepens Global Collaboration with AstraZeneca to Advance Next Generation Biotherapeutics

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...

November 25, 2025 | News

Kelun Biotech Reports Strong Phase Three Success for Sac TMT and Keytruda in First Line Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that the Independent Data Monitoring Committee (IDMC) concluded t...

November 25, 2025 | News

Everest Medicines Begins Global Phase I Trial of EVM14 as First Patient Receives Dose in the United States

The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated ...

November 24, 2025 | News

China Marks a Landmark Moment as BioDlink and Lepu Biopharma Launch the World’s First EGFR Targeting ADC

Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their par...

November 24, 2025 | News

Henlius Therapy Wins Breakthrough Designation as First Immunotherapy Led Perioperative Regimen for Gastric Cancer

The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer p...

November 21, 2025 | News

Guided Therapeutics Secures New LuViva Supply Agreement to Expand Cervical Cancer Screening Reach in China

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced it had completed an initial supply agreement with Yuansh...

November 21, 2025 | News

Tsingke Biotech Showcases Breakthrough Speed in Protein and Antibody Development at PEGS Europe 2025

At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest ac...

November 20, 2025 | News

YolTech Therapeutics Receives FDA Clearance to Begin Pivotal Trial for In Vivo Gene Editing Therapy in PH1

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food ...

November 20, 2025 | News

Shanghai Henlius and Organon Achieve FDA Approval for POHERDY, First Pertuzumab Biosimilar in the US

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has approved the Biologics...

November 19, 2025 | News

Stay Connected